Subtype
Bladder Neoplasm
CI-CAN-00001978Explore in graph →
Non-malignant390 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001978Explore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03307200 | Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy | completed | — | 90 | University Hospital, GhentOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04598724 | Addressing Barriers to Palliative Care Use in Bladder Cancer | completed | — | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT00805129 | Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT03980041 | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) | completed | Phase 2 | 49 | Infinity Pharmaceuticals, Inc.INDUSTRY | 7 | Nov 25, 2022 | clinicaltrials |
| NCT03066310 | Urine-DNA Biomarkers in Detecting Bladder Cancer | completed | — | 125 | Xiangya Hospital of Central South UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT03325231 | Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy | completed | — | 140 | Swansea UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT03584659 | Patient-reported Outcomes in Bladder Cancer(iBLAD) | completed | N/A | 230 | Rigshospitalet, DenmarkOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01688999 | Cabozantinib for Advanced Urothelial Cancer | completed | Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02437370 | Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer | completed | Phase 1 | 32 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02811952 | Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients | completed | — | 100 | Carmel Medical CenterOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00199849 | NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine | completed | Phase 1 | 18 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00188695 | Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide | completed | Phase 1 / Phase 2 | 61 | University Health Network, TorontoOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01869413 | Tranexamic Acid During Cystectomy Trial (TACT)(TACT) | completed | Phase 2 / Phase 3 | 354 | Ottawa Hospital Research InstituteOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT02500121 | Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | completed | Phase 2 | 108 | Matthew GalskyOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT03505112 | The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy | completed | N/A | 82 | Seoul National University HospitalOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03558503 | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer(OPTIMA II) | completed | Phase 2 | 63 | UroGen Pharma Ltd.INDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03773666 | A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) | completed | Phase 1 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03662204 | Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors | completed | — | 5,133 | Exact Sciences CorporationINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05376631 | Effect of Fresh Gas Flow on Emergence Time | completed | N/A | 54 | Asan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05184725 | CARINAE for Stress Relief in Perioperative Care(CARINAE) | completed | N/A | 50 | Adhera Health, Inc.INDUSTRY | 3 | Aug 1, 2022 | clinicaltrials |
| NCT03458598 | Pre-Operative Single Shot Rectus Sheath Block | completed | N/A | 49 | University of AlbertaOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT01780545 | Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer | completed | Phase 2 | 200 | Noah Hahn, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02993211 | Transurethral En Bloc Versus Standard Resection of Bladder Tumour | completed | N/A | 350 | Chinese University of Hong KongOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT00777491 | Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery | completed | Phase 2 | 70 | Radiation Therapy Oncology GroupNETWORK | 2 | Jun 15, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05082818 | Outcome of Treating Bladder Cancer in Sohag University Hospital | completed | — | 168 | Sohag UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05362539 | Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria | completed | N/A | 246 | Mansoura UniversityOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT03628716 | CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer | completed | Phase 2 | 43 | Bavarian NordicINDUSTRY | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05290623 | High-power Green-light Laser Endoscopic Submucosal Dissection for Non-muscle-invasive Bladder Cancer | completed | — | 45 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05273593 | Confocal Laser Endomicroscopy During TransUrethral Resection for Improving BC Diagnosis and Treatment(CLETUR) | completed | N/A | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT04570176 | Efficacy and Safety of Clinical Telesurgery Using Chinese Independently Developed Surgical Robot System | completed | N/A | 1 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT04316689 | First-in-human Study of S-588210 (S-488210+S-488211) | completed | Phase 1 | 10 | ShionogiINDUSTRY | 1 | Jan 26, 2022 | clinicaltrials |
| NCT01935466 | Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"(PROBE-PIO) | completed | — | 6,107 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT00710970 | Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | completed | Phase 2 | 28 | Seth LernerOTHER | 2 | Jan 24, 2022 | clinicaltrials |
| NCT02966691 | Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors(VISIOCYT 1) | completed | N/A | 1,360 | VitadxOTHER | 1 | Jan 6, 2022 | clinicaltrials |
| NCT03689478 | Use of Immediate Hyperthermic Intravesical Chemotherapy Following TURBT(I-HIVEC) | completed | N/A | 30 | Chinese University of Hong KongOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03294304 | BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy | completed | Phase 2 | 43 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT01738815 | Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer | completed | Early Phase 1 | 43 | State University of New York - Upstate Medical UniversityOTHER | 1 | Oct 22, 2021 | clinicaltrials |
| NCT04190641 | Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder | completed | N/A | 4 | Ambu A/SINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jan 6, 2023source: clinicaltrials